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A spectrophotometric method for the determination of total and 
free carnitine was adapted to the Cobas Bio Fara centrifiigal analyser. 
The method employed a highly specific enzyme carnitine 
acetyltransferase to acetylate L-camitine with the subsequent release of 
coenzyme A, which was coupled to 5,5'-dithiobis(2-nitrobenzoate) 
(DTNB) to give a yellow compound which was monitored at 412nm. 
The assay was linear over a wide range of carnitine concentration. The 
precision and recovery were satisfactory. Ultrafiltration was employed 
for deproteinization of the specimens. 
In the clinical study，two patients with cardiomyopathy were 
found to be carnitine deficient, one primary and the other secondary. 
One patient with suspected metabolic disease had very high urinary total 
and free carnitine excretion and was also compatible with secondary 
carnitine deficiency. Both patients on valproic acid therapy or on renal 
dialysis had low plasma carnitine and a high acyl to free carnitine ratio. 
The underlying mechanisms, however, were different. Post renal 
transplant patients tended to have a normal carnitine profile. 
• 1 _ 
In conclusion，the spectrphotometric method for carnitine is useful 
for screening of carnitine problems in patients with cardiomyopathy and 
suspected metabolic disorders. It is also useful to monitor the carnitine 
status in patients on valproic acid and renal transplant therapy, 




Carnitine has a long history in biochemistry. It was discovered to 
be a quantitatively important compund in 1905 (Gulewitsch & 
Krimberg, 1905). Its chemical structure, 3-hydroxy-4-trimethylamino-
butyrate was established in 1927 (Tomita & Sendu，1927). In 1959，it 
was found to be related to long-chain fatty acid oxidation (Fritz, 1959). 
The structure of carnitine is given below. 
CH3 H 
CH3 - N+_ CH2 - C _ CH2 _ COO-
CH3 OH 
Two isomers of carnitine have been identified, namely, the L-
isomer and D-isomer. They are natural isomers. However, only the L-
isomer is biologically active, although the D-isomer can also be 
absorbed. D-isomer can function as an exchange agent for intracellular 
L-isomer. In this thesis, carnitine refers to L-camitine unless D-camitine 
is specified. 
There are two sources of carnitine in the body : dietary and 
endogenous synthesis. Major organs, such as liver, heart and kidney can 
synthesize carnitine. The highest concentration of carnitine in our diet 
is found in red meat and dairy products. Vegetables, cereals and fruits 
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contain little or no carnitine at all. Carnitine in food exists usually as free 
carnitine, and to a minor extent in esterified forms. Dietary carnitine is 
easily and completely absorbed like the water-soluble vitamins (Haeckel 
et al, 1990). 
As carnitine determination becomes more widely available, it has 
become more evident in the past decade that carnitine is involved in 
many different aspects in human diseases. 
Primary carnitine deficiency, most commonly due to a defect in 
carnitine transport across the tissues, is relatively rare. Secondary 
carnitine deficiency, due to the loss of carnitine in the process of 
removal of toxic acyl groups from the body, is more common. 
Carnitine deficiency has been reported in many metabolic diseases 
and clinical conditions, such as cardiomyopathy. Improvement in the 
clinical condition has been observed with carnitine supplementation. 
Therefore, the role of carnitine in clinical medicine cannot be ignored. 
The purpose of this project is to establish a rapid and reliable method for 
carnitine determination and to study the carnitine status in patients with 
cardiomyopathy, suspected metabolic diseases, on valproic acid therapy 
and on renal replacement therapy. 
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2. BASTC ASPECTS OF CARNITINE 
2.1 Biosynthesis of carnitine 
The four-carbon chain of carnitine comes from the protein-bound 
amino acid lysine while the three methyl groups are contributed by 
another amino acid methionine. The biosynthesis pathway involves a 
sequence of five enzymes (Figure 1). Lysine is first methylated to form 
6-N-trimethyllysine. It is hydroxylated aerobically to 3-hydroxy-6-N-
trimethyllysine with ascorbate and ferrous ions as cofactors. Under the 
action of aldolase and then dehydrogenase, 4-N-trimethyl-
aminobutyraldehyde and 4-N-trimethylaminobutyrate (deoxycamitine 
or 4-butyrobetaine) are formed respectively. Finally, 4-butyrobetaine is 
hydroxylated to form carnitine, both ascorbate and ferrous ions are 
required as cofactors. 
Most tissues contain the enzymes necessary to convert 6-N-
trimethyllysine to 4-butyrobetaine. However, 4-butyrobetaine 
hydroxylase, the last enzyme in the sequence, is present only in liver, 
kidney and brain (Siliprandi et al, 1989). Thus, other tissues, such as 
0 
muscle, have to export the precursor 4-butyrobetaine through the 
circulation to the hydroxylating tissues to complete the synthesis. 
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In addition, an inter-organ transport of carnitine presursors also 
‘ I 
occurs (Figure 2). For instance, 6-N-trimethyllysine is released by 
muscle, which contains the largest amount of it, and is taken up by the 
kidney to be converted into 4-butyrobetaine and carnitine. Indeed, the 
kidney has a large capability to take up 6-N-trimethyllysine from blood 
and a high capacity of converting them into 4-butyrobetaine and 
carnitine through its hydroxylase activities. Ultimately, newly 
synthesized carnitine is released back to the circulation. 
• � - 6 -
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Figure 1. Biosynthetic pathway of carnitine. 
(Adapted from Haeckel et al, 1990) 
LIVER MUSCLES � KINDEY 
6-N-trimethyllysme 6-N-trimethyllysine > 6-N-trimethyllysine 
I ^ 
4-N-trimethylainin- 4-N-triinethylammo- ^ 4-N-trimethylamino-
butyraldehyde butyraldehyde butyraldehyde 
、‘ I ^ 
4-trimethylamino-butyrate < ~ 4-trimethylamino-butyrate ~ > 4-trimethylamino-butyrate t I � / r . 
carnitine ^ carnitine ^ carnitine 
Figure 2. Inter-organ transport of carnitine and its intermediates, 
(see text for explanation) 
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2.2 CARNTTTNE TRANSPORT 
The physiological functions of carnitine depend on a transport 
system that ensures adequate carnitine concentration in the tissues and 
appropriate distribution in intracellular compartments. The need for this 
transport system is illustrated by several features of normal carnitine 
homeostasis : 
(1) Carnitine is a quaternary amine and it cannot diffuse across lipid 
membranes readily; 
(2) Although required by all tissues, camtine synthesis is 
predominantly completed in the liver. 
(3) Carnitine absorption from the gastrointestinal tract is important; 
(4) The concentration of carnitine in tissues is much higher than in 
plasma, hence the transport of carnitine into tissue would be 
against a significant concentration gradient. 
(5) Being a small and water-soluble molecule, carnitine is readily 
filtered by the glomeruli. Reabsorption is required to prevent 
excessive loss in the urine. 
(6) Since carnitine functions both in the mitochondrial matrix and 
extramitochondrial space, it must be able to cross the permeability 
barrier of the inner mitochondrial membrane. 
• • 
Each of these requirements is facilitated by a group of active 
sodium-dependent transport systems (Hamilton et al, 1983). They are 
essential for the uptake of carnitine from extracellular fluid in the tissue, 
although definitive mechanisms are not available. As fatty acid beta-
oxidation occurs primarily in the mitochondrial matrix, long-chain 
acylcamitines must transverse the mitochondrial inner membrane. In the 
matrix, the conversion of acylcamitine to acyl CoA will generate 
carnitine. Thus, a mechanism must exist for import of acylcamitine and 
export of carnitine. The mitochondrial camitine-acylcamitine translocase 
was then identified which was responsible for the inner mitochondrial 
carnitine transport (Pande，1975). It was a temperature (Pande, 1975)， 
but not energy-dependent (Pande & Pavin，1976) process. 
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2.3 THE ROLE OF CARNITINE TN INTRACELLULAR 
METABOLTSM 
The best described function of carnitine in intracellular 
metabolsim is in the mitochondrial oxidation of long-chain fatty acids. 
Palmitate is used as an example of long-chain fatty acid to explain the 
process. 
The conversion of palmitate to palmitoyl CoA occurs in the 
endoplasmic reticulum (microsomal fraction) and on the outer surface 
of the mitochondrial outer membrane via a long-chain acyl CoA 
synthetase. The palmitoyl CoA must then pass through the 
intermembrane space of the mitochondria. While palmitoyl CoA is the 
substrate for beta-oxidation in the mitochondria matrix, it cannot pass 
through the inner membrane. The palmitoyl CoA is converted to 
palmitoylcamitine by an "outer" carnitine palmitoyltransferase (CPT). 
The location of this CPT activity is still uncertain. The enzyme activity 
was originally described by Hoppel and Tomed (1972) and by Brosnan 
et al (1973) to be localized on the outer surface of the inner membrane. 
The work ofMurthy and Pande (1987) has placed this CPT activity on 
the inner surface of the outer membrane. In both of these locations the 
enzyme was found facing the same compartment. 
-10 -
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The palmitoylcamitine is then transported across the 
mitochondrial inner membrane via a carnitine acylcamitine translocase 
which is an antiport system with carnitine from the matrix exchanging 
with the palmitoylcamitine. The matrix palmitoylcamitine is a substrate 
for an inner CPT using matrix CoASH to form palmitoyl CoA in the 
matrix and release carnitine. The palmitoyl CoA enters the beta-
oxidation pathway, being acted upon by the long-chain acyl CoA 
dehydrogenase. Thus, carnitine is an obligate in the transfer of the long-
chain acyl group across the mitochondrial inner membrane to the site of 
beta-oxidation. The process is illustrated in figure 3. Thus, the major 
function of carnitine in intracellular metabolism is the import of long-
chain acyl group into the mitochondrial matrix for beta-oxidation. 
- 1 1 -
‘ H i • 
PPi + AMP + PalmitoyI CoA “ PalmitoyI CoA + Carnitne Carnitine + PalmitoyI CoA 
N. f ~ ’ -Jf ^ z ^ARNITINg) 
"SSSSS? g^n^ ^^ CoASH + Palmitoylcarnitine^ '^^ »^ Palmitoylcamitne + CoASH 
Mi^ orhondri.! B^ xidation Lone-chain fatty acids are activated by palmitoyi CoA synthetase. The CoA ester 
^ r：^^ b/enx^ o f t citric acid 一 and the respiratory 
Figure 3. Mitochondrial oxidation (see text for detailed explanation). 
(Adapted from Scholte et al, 1990) 
• 
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Carnitine is also involved in the export of short-chained 
acylcamitine (acetyl, propanoyl, branched-chain acylcamitine) from 
mitochondria. The export of the acetyl group as acetylcamitine most 
commonly occurs when the formation of acetyl CoA exceeds its 
utilization in the citric acid cycle. In conditions of carnitine 
insufficiency, acetyl CoA accumulates in the matrix, where they inhibit 
pyruvate dehydrogenase activity (Kerbey et al, 1976). 
The export of branched-chain acyl groups in the form of 
branched-chain acylcamitine is critical in the catabolism of leucine, 
isoleucine and valine (Bremer, 1983). For example, conversion from 
isovaleryl-CoA to isovaleryl carnitine is essential for the transport of the 
isovaleryl group out of the mitochondria (Figure 4). Otherwise, 
accumulation of isovaleryl CoA, either as a consequence of 
overproduction (isovaleryl acidaemia)(Chalmers et al, 1984) or due to 
carnitine deficiency, may cause metabolic alterations. An 
overproduction of short-chain CoA thioesters causes depletion of 
carnitine (Chalmers et al, 1983), since the disposal of these 
intermediates takes away part of the otherwise normal cellular content 
of carnitine. It has to be pointed out that the function of camitine-
dependent transferases (e.g. carnitine palmitoyltransferase) can be 
-13 -
/ 
altered not only by a reduction of intracellular carnitine, but also by an 
accumulation of long-chain acyl-CoA or by acidosis, both conditions 
leading to a decrease in the affinity for carnitine (Chase, 1967). 
Furthermore, the accumulation of short-chain acylcamitines can also 
inhibit the activity of carnitine acetyl-transferase, which shows a 
prominent product inhibition effect (Bieber, 1988). 
Some xenobiotics，for example, valproic acid can form thioesters 
with CoASH. It is metabolized in the liver and is converted to valproyl-
CoA which is toxic to the body. In an exchange reaction, the metabolite 
forms a carnitine ester, which is excreted in the urine. Valproic acid 
therapy may consequently induce carnitine deficiency (Millington et al, 
1985). 
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Figure 4. Mitochondrial leucine metabolism leading to isovaleryl 
carnitine formation (see text for explanation). 
-15 -
2.4 THE ROLE OF KTDNEY IN CARNITINE METABOLISM 
The kidney has multiple functions in carnitine homeostasis, it is 
involved in: 
(1) biosynthesis; 
(2) tubular reabsorption; 
(3) excretion and 
(4) acylation and deacylation. 
The biosynthesis of carnitine in kidney is similar to other organs. 
Carnitine is freely filtered but reabsorbed in the proximal tubule. A 
sodium dependent transport system has been proposed in the proximal 
tubular brush border membranes (Rebouche and Mack, 1984). A defect 
of this mechanisn is believed to be a cause for systemic carnitine 
deficiency. 
On the other hand, carnitine seems to be secreted into the tubular 
lumen by another mechanism (Scholte et al, 1990) because the renal 
excretion rate of total carnitine can exceed the glomerular filtration rate. 
The fact that the urinary acylcamitine to free carnitine ratio exceeds that 
of plasma indicates a preferential excretion of acylcamitine and 
reabsorption of free carnitine in the proximal tubule. This may also 
points to a possible role of renal tubule in carnitine acylation. 
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According to Guder and Wagner (1990)，acylation of carnitine 
may take place in the tubule cells during the secretory process. High 
activities of both cytosol and mitochondrial carnitine acetyltransferase 
have been found in the kidney. Proximal tubule cells actively take up 
carnitine and convert it to acyl derivatives. Since acyl derivatives 
predominate in urine, it seems that the newly formed carnitine esters are 
secreted into the tubular lumen. This acylation is indeed a detoxification 
process so that excess acyl groups are excreted out. So, the kidney does 
not only play a role in carnitine biosynthesis, its reabsorptive and 
secretory capacities are also of importance. Indeed, it is a major organ 
for regulation of the whole body's carnitine status. 
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3- CARNITINE DEFTCTENCY 
Carnitine deficiency is the reduction of intracellular free carnitine 
level, leading to a decrease of acyl transport out of the inner membrane 
and the accumulation of acyl-CoA esters. There are several 
consequences : 
(1) Intracellular free carnitine becomes too low to sustain fatty acid 
oxidation in mitochondria. Glycogen and glucose are then the 
preferred substrates. Fasting causes a lack of energy in organs 
depending upon fatty acids as energy source. This results in the 
failure of the function of the heart, skeletal muscle and/or liver 
causing brain damage, by hypoglycaemia, and 
hyperammonaemia. 
(2) The increased acyl-CoA esters inhibit many enzymes and carriers. 
In particular, the long-chain acyl-CoA is a potent inhibitor of 
metabolism. It significantly reduces both the mitochondrial and 
glycolytic ATP production by inhibiting the adenine nucleotide 
carrier at both sides of the mitochondrial inner membrane and also 
the enzyme 3-phosphoglycerate dehydrogenase. Long-chain acyl-
CoA also interferes with other enzymes such as NAD(P) 
transhydrogenase, glutamate dehydrogenase (affecting hepatic 
-18 -
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urea synthesis and cerebral glutamate metabolism) and carnitine 
acetyltransferase (leading to further disturbance of acetyl export). 
(3) Carnitine depletion also hinders the export of acetyl group from 
the mitochondrial matrix to the cytosol by the carnitine system. 
This inhibits biosynthetic processes that requires acetyl-CoA, 
such as acetylcholine synthesis in the nervous system. 
In spite of the low tissue carnitine levels, some patients with 
carnitine deficiency may be in perfect health. This is probably due to the 
following factors : 
(1) Prolonged fasting is not common. 
(2) A small amount of free carnitine is sufficient to drive the carnitine 
system. 
(3) The intracellular concentration of long-chain acyl-CoA is 
decreased by the action of many enzymatic reactions, especially 
in liver, and also by binding to the proteins and to the lipid 
domain of membranes. 
-19 -
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3.1 PRTMARY CARNTTTNE DEFICIENCY 
Primary carnitine deficiency may be caused by one or more 
of the following defects : 
(1) Impaired carnitine synthesis due to 
(a) genetic alteration of some of the enzymes involved in the 
synthetic process. 
(b) lack of carnitine substrates (lysine and methionine) or 
deficiency of the cofactors (ascorbate and iron) needed in 
some steps of the synthetic pathways. 
(2) Altered renal reabsorption. 
(3) Impaired transport in tissues. 
1 
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Two forms of primary carnitine deficiency, both potentially lethal, 
are recognized: 
3.1.1 MYOPATHIC CARNTTINE DEFTCTENCY 
Carnitine is decreased in skeletal muscle and sometimes also in 
heart muscle. There is progressive muscle weakness. Plasma carnitine 
is normal or slightly low, however, liver carnitine is normal and this 
helps to distinguish it from the systemic form. The deficiency was 
attributed to a defect in the carnitine importing protein in the plasma 
membrane of skeletal muscle. 
3.1.2 SYSTEMIC CARNTTTNE DEFICIENCY 
Carnitine is decreased in all tissues and the plasma carnitine 
concentration is very low. In these patients, neutral fat accumulates in 
muscle and other organs. The symptoms of patients with this type of 
carnitine deficiency are progressive muscle weakness, cardiomyopathy, 
hepatopathy and/or encephalopathy. Life threatening attacks of heart or 
liver failure may occur, which are precipitated by fasting. 
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3.2 SECONDARY CARNITINE DEFTCTENCY 
Secondary carnitine deficiencies are a heterogenous group of 
disorders sharing a common characteristic of abnormal accumulation of 
metabolic intermediates or exogenous compounds capable of reacting 
with CoA. The consequent shortage of free CoA, otherwise deleterious 
for mitochondrial oxidative process (Hulsmann et al, 1964)，may be 
prevented or attenuated by carnitine through the formation of 
acylcamitine which, unlike the corresponding acyl CoA, may be 
released from mitochondria and the cell. Secondary carnitine deficiency 
may be accompanied by a moderate degree of muscular dysfunction. 
Liver or cardiac muscle involvements are uncommon. 
Normal and abnormal and abnormal acylcamitine, formed in these 
conditions, are released from tissues into plasma and preferentially 
excreted in urine. In addition, the ratio of acyl to free carnitine is 
increased because the block in the oxidation of acyl CoA compounds 
increased their esterification with free carnitine to form acylcamitine. 
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4. CARNTTTNE METABOLISM TN SELECTED DISEASES 
4.1 rARDTOMYOPATHY 
In children, cardiomyopathy is a heterogeneous group of rare 
disorders often considered to be "idiopathic" (Kohlschutter and 
Hausdorf, 1986). Primary carnitine deficiency can lead to 
cardiomyopathy. It is caused by inadequate tissue carnitine to carry out 
fatty acid beta oxidation. The plasma carnitine concentration is very low 
in the systemic type, rarely plasma carnitine may be normal but muscle 
carnitine is low, as seen in the myopathic type. 
On the other hand, several inborn errors of metabolism may also 
cause cardiomyopathy. These inherited conditions can be roughly 
divided in two main groups : 
(1) "Large" molecule diseases such as glycogen storage diseases, 
lysosomal storage diseases; 
(2) "Small" molecule diseases such as organic acidurias, beta-
oxidation defects. 
Secondary carnitine deficiency has been associated with "small" 
molecule diseases because carnitine plays a crucial role in the regulation 
of intramitochondrial acyl CoA / CoA ratio as described in the organic 
acidurias section. Excessive intracellular acylcamitines are cleared 
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through the bloodstream and excreted in the urine. Therefore, the free 
carnitine is low and acylcamitine is high in the plasma, with elevation 
of the acyl to free carnitine ratio. So, evalution of plasma carnitine 
profiles is helpful in the identification in patients with "small" molecule 
diseases. Carnitine measurement has been advocated in patients with 
idiopathic cardiomyopathy. 
4.2 O^r^ANTr ArTDTIRTAS 
Organic acidurias are genetic disorders of mitochondrial 
metabolism (Chalmers, 1989), which lead to the accumulation in tissues 
and biological fluids of unmetabolised organic acids. They include 
defects in catabolism of straight-chain fatty acids in beta-oxidation 
caused by deficiency of long-, medium- or short-chain acyl CoA 
dehydrogenase and branched-chain amino acids. 
Carnitine plays an important role by buffering the excess of 
unmetabolized acyl CoAs which accumulates in mitochondria. To 
compensate for this, the equilibrium of the reaction : 
Acylcamitine + C o A � � A c y l C o A + L-camitine 
shifts to the left and in this way, free carnitine is depleted. The CoA / 
acyl CoA ratio in the mitochondrion is returned back towards normal. As 
this process continues, acylcamitines accumulate and pass out of the 
-24 -
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mitochondria, out of the cell and into the plasma. The ratio of 
acylcamitine to free carnitine in plasma is then increased, and because 
acylcamitines have a low renal threshold, there is a net loss of carnitine 
into the urine, which leads to systemic carnitine deficiency. 
) 
The acyl CoA dehydrogenation deficiencies comprise a group of 
inborn enzymatic defects in beta-oxidation of fatty acids. These defects 
include long-chain acyl CoA dehydrogenase (LCAD), medium-chain 
CoA dehydrogenase (MCAD) and short-chain acyl CoA dehydrogenase 
(SCAD) deficiencies. They all cause secondary carnitine deficiency with 
increase in esterified carnitine. MCAD deficiency has been recognized 
to be one of the most frequent genetic metabolic diseases. Two MCAD 
patients on carnitine therapy had improved urinary organic acid profile, 
reduced hepatomegaly and reduced number of metabolic attacks. 
However, in other patients, carnitine therapy was unable to influence the 
clinical course or restore muscle carnitine content to normal (Treem et 
al, 1989). 
Carnitine measurement in patients with suspected metabolic 
diseases or organic aciduria may help to detect MCAD deficient 




4.3 VAT.PROTC ACTD THERAPY 
Valproic acid (VPA) is a branch-chain fatty acid used in the 
treatment of epilepsy. It is largely metabolised in the liver and 
eliminated mainly in the urine. Valproic acid is thought to inhibit beta-
oxidation by sequestering coenzyme A, and by the accumulation ofnon-
acetyl CoA esters, possibly valproyl-CoA in mitochodria. The decrease 
in the concentration of coenzyme A would limit the activities of some 
coenzyme A dependent enzymes. One result would be a fall in acetyl-
CoA, the final product of beta-oxidation. 
Treatment with valproic acid has been associated with decreased 
carnitine in plasma and a high ratio of acylcamitine to free carnitine. A 
renal loss of carnitine occurs when carnitine esters are finally excreted. 
VPA is widely used, both alone and as a component of multidrug 
regimens. Therapy with VPA may be associated with reversible hepatic 
dysfunction, irreversible hepatic coma accompanied with hepatocellular 
necrosis, or hyperammonaemia without clinical evidence of hepatic 
injury (Gram, 1983). Up to 44% of VPA treated patients have abnormal 
liver function tests (Dreifuss et al, 1987)，which normalize after the dose 
is decreased or the drug is discontinued. Such results are more common 
in patients who are receiving valproate as part of a multidrug regimen. 
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The overall incidence of fatal hepatotoxicity is low (Jeavons， 
1984). The highest frequency was found in children up to two years old 
who were receiving the drug as part of a multidrug regimen 
(Dreifuss,1987). The incidence declined with age. 
The mechanism by which VPA causes liver damage is still not 
well understood. VPA hepatotoxicity is believed to be mediated by some 
of its metabolites, and particularly by its unsaturated biotransformation 
products, 4-en-VPA. It potentially inhibits mitochondria fatty acid 
metabolism by destroying 3-ketoacyl-CoA thiolase, the last enzyme in 
the beta-oxidation complex (Schulz, 1983). VPA undergoes desaturation 
to 4-en-VPA in liver microsomes, presumably via cytochrome P-450 
(Rettie, 1987); 4-en-VPA may undergo further enzymatic activation to 
chemically reactive species with hepatic properties (Rettenmeier, 1985). 
This metabolic transformation might be enhanced by previous or 
concomitant treatment with enzyme inducers such as phenobarbital. 
There is no clear relationship between hepatotoxicity and carnitine 
status in patients on valproic acid. There is also no evidence that 
carnitine supplementation will reduce fatal hepatotoxicity. 
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4.4 RENAL DTALYSTS AND TRANSPLANTATION 
Carnitine metabolism is largely affected by the kidney functions. 
Under normal conditions, circulating carnitine is freely filtered in the 
glomeruli and most of the filtered free carnitine is reabsorbed by the 
renal tubules. Compared with acylcamitine, free carnitine is 
preferentially reabsorbed, thus renal clearance of acylcamitine is many 
folds higher than that of free carnitine (Guamieri et al,1988). With the 
declining glomerular filtration rate in renal failure, carnitine filtration 
also decreases leading to elevated plasma carnitine levels. With 
progressive renal disease, the tubular handling of carnitine and its esters 
becomes abnormal. The preferential reabsorption of free carnitine and 
excretion of acylcamitine by the renal tubules is impaired leading to a 
marked increase in plasma acylcamitine. In patients who are not on 
dialysis, both free and total carnitine concentrations are increased and 
the ratio of acyl to free carnitine is high as compared with normal 
subjects. In patients undergoing continuous ambulatory peritoneal 
dialysis and hemodialysis (Bohmer et al, 1978 & Moorthy et al, 1983)， 
total carnitine appears to be normal, but the acyl to free carnitine ratio 
is significantly high. Not much is known about carnitine status after 
kidney transplantation. 
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Abnormal carnitine metabolism is common in dialysis patients. 
Impairment of muscle function and metabolism, muscle weakness and 
myopathy, cardiac dysfunction, cardiomyopathy, arrhythmias, and 
plasma lipid abnormalities have been reported in these patients. At least 
42 studies of L-camitine supplementation in 600 dialysis patients have 
been reported (Ahmad, 1992). The supplementation is associated with 
a severalfold increase in plasma concentration of free carnitine as well 
as acylcamitine. The abnormal ratio of acyl to free carnitine improves 
with carnitine supplementation (Ahmad, 1992). Clinically benefits are 
observable in most of the studies. Total and free carnitine determination 
are therefore useful in the management of renal patients. 
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5. ANALYTICAL METHODS FOR CARNTTTNE ASSAYS 
The original method for determination of carnitine was a bioassay 
based on camitine-dependent growth of the mealworm Tenebrio molitor 
(Fraenkel G.，1954). Later, Friedman (1958) introduced a spectro-
photometric assay based on bromophenol blue dye binding to 
acylcamitine esters. Marquis and Fritz (1964) developed a more direct 
spectrophotometric assay for measurement of L-camitine by using the 
carnitine acetyltransferase reaction. Afterwards, a number of 
spectrophotometric methods had developed based on the catalytic 
activity of this enzyme. Carnitine can be determined at the nanomole 
level. Spectrophotometric method becomes popular because it is simple, 
rapid, relatively cheap and automation is possible. 
The drawback of the spectrophotometric method is that the 
sensitivity is not very high, it is still satisfactory for a general screening 
purpose. Higher sensitivity can be obtained by the radioenzymic method. 
It combines the specific enzymatic reaction catalyzed by carnitine 
acetyltransferase and the highly sensitive isotopic labelled carbon 
incorporated into the acetyl CoA. The detection level is down to the 
picomole level. The main disadvantage of this method is the hazard of 
radiation. 
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Chromatographic technique has also been developed for the 
determination of carnitine. Instrumentation is expensive, technical 
expertise is required and it may not be suitable to handle large number 
of samples. The chromatography techique has, however, a distinct 
advantage that cannot be replaced by other methods. Instead of giving 
either the total or free carnitine levels as other methods do, it can analyse 
the whole profile of carnitine and acylcamitine at a single run. The acyl 
groups can be specified and is useful in diagnosing specific diseases. 
A spectrophotometric method was chosen for this project. It 
employed the specific enzymatic reaction and was relatively cheap, easy 
to monitor, simple to operate. The method can be automated to handle 
a large workload. 
A statistical way to compare the results of the patients with the 
controls is by using the student's t test. 
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6. DFTFRMTNATTON OF TOTAL AND FREE CARNITINE 
6.1 PPTNCTPT E OF THE ASSAYS 
Carnitine was determined by the method of Roe et al, 1992. 
Plasma or urine sample was deproteinized by passing through 30,000 
molecular weight cut-off ultra-spin filter using a microcuvette desktop 
centrifuge. An aliquot of the filtrate was analysed directly and the result 
would give an estimation of the free carnitine. Another aliquot was 
hydrolysed by NaOH to release free carnitine from the acyl group of 
the esterified carnitine. Total carnitine, ie，the free and the acyl 
components, could then be determined. 
6.1.1 FttFF rARNTTTNF PETERMTNATION 
Free carnitine is determined enzymatically by the following two 
reactions (Pearson, 1969) : CAT 
L-Camitine + Acetyl-CoASH > Acetyl L-camitine + CoASH 
CoASH + DTNB > CoA-S-NB + TNB' + IT 
In the presence of acetyl-CoA and carnitine acetyltransferase 
(CAT), free carnitine is acetylated and CoASH is formed. CoASH 
reacts with 5,5'-dithiobis-2-nitrobenzoate (DTNB) to form the yellow 5-
thio-2-nitrobeiizoate anion (TNB ) which can be measured at 412 nm. 
The amount of TNB" formed is proportional to the L-camitine 
concentration. The pH for the optimal enzymatic reaction is about 7.5. 
-32 -
6.1.2 TOTAL CARNTTTNE DETERMINATION 
For the determination of the total carnitine, an alkaline hydrolysis 
step is required prior to the analysis. Sodium hydroxide is used to 
hydrolyse the esterified carnitine (acylcamitine) to release the free 
carnitine and the acyl group (Pearson, 1969). 
Esterified L-camitine + NaOH > Acyl group + free L-camitine 
(Acylcamitine) . 
Hydrochloric acid is required to neutralize the NaOH and pH is 
adjusted to approximately 7.5. After the hydrolysis, the product is 
subjected to carnitine measurement. 
The concentration of acylcamitine can be calculated by 
subtracting the free carnitine from the total carnitine concentration. 
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6.2 TNSTRIJMENTATTON 
(1) The CoBas Bio Fara centrifugal analyser from Roche Diagnostics 
was employed. 
It is a single unit centrifugal analyser which utilizes the 
unique horizontal light path principle. The robotic pipettor arms 
are capable of randomly selecting and loading several reagents, 
sample diluent and pretreatment solution into a thirty place 
disposable plastic cuvette rotor. Each cuvette has two 
compartments, one for reagent and one for sample and additional 
reagents if required. The reagent and sample are thus kept 
separate until the rotor accelerates and mixes by means of 
vibration and braking. The rotor then stops for pipetting a second 
reagent. The rotor accelerates and the next reaction begins. 
The absorbance measurements are made using a horizonal 
placement of cuvettes relative to the light path. This feature 
allows lower reagent volume and the optimum photometric range 
can be varied by the reaction volume. The wavelength is selected 
by a motor driven holographic grating monochromator. 
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(2) lEC Centra - M2 microcuvette desktop centrifuge from 
International Equipment Company, U.S.A. 
This is a fixed angle desktop centrifuge with twenty-two 
chambers specially for microcuvette centrifugation. It can 
generate a centrifugal force of more than ten thousand 
gravitational force when fiilly loaded. The adjustment of 
gravitational force is by means of a scaled speed knob. 
(3) Molecular weight (30,000) cut-off ultra-spin filters from Lida 
Manufacturing Corp. U.S.A. 
The membrane is made up of polysulfone. It consists of a very 
thin and dense skin laid on top of a macroporous support. A 
microcuvette centrifuge with centrifugal force not exceeding 
2,500g was used. The amount of albumin claimed to be retained 
by a 30,000 molecular weight cut-off filter is over 98%. It is not 
reusable and the maximum sample volume is 400 ul. 
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6.3 PREPARATION OF THE REAGENTS AND STANDARDS 
Reagents 
(1) HEPES, N-2-Hydroxyethylpiperazine-N'-2-ethanesulphonic acid, 
C8H18N2O4S, pKa = 7.5 at 25®C, pH range : 6.8-8.2 (Sigma). 
I 
I 
I Storage : room temperature 
i 
5) 
Formula weight: 238.3 g 
(2) EDTA，Ethylene diaminetetra-acetic acid, anhydrous, C10H16N2O8, 
(Sigma). 
Storage : room temperature 
J 
Formula weight: 292.2 g 
i 
(3) MOPS, 3-[N-morpholino]propanesulfonic acid, C7H15NO4S, 
pKa 二 7.2 at 25^C, pH range : 6.9-7.5 (Sigma). 
Storage : room temperature 
Formula weight: 209.3g 
(4) DTNB, 5,5'-Dithio-bis(2-nitrobenzoic acid), C14H8N2O8S2, 
(Sigma). 
Storage : room temperature 
Formula weight: 396.3 g 
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(5) KOH，Potassium hydroxide, pellets, 'AnalaR' (British Drug 
House). 
Storage : room temperature 
Formula weight: 56.11 g 
(6) HCL, Hydrochloric acid,丨AnalaR,，37% HCL/L, specific gravity 
=1.19 (British Drug House). 
Storage : room temperature in safety cabinet 
Formula weight: 36.46 g 
(7) Acetyl Coenzyme A, sodium salt, C23H38N7O17P3S, (Sigma) 
Storage : -20^C 
Formula weight: 809.6 g 
(8) Carnitine Acetyltransferase, suspension in 3.2 M 0^4)2804, 
pH 7.0, (Sigma). 
Storage : 4®C 
Activity : 10.6 mg in 2 ml suspension per bottle 
100 units / mg protein 
(9) L-camitine hydrochloride, C7H15NO3HCL, (Sigma). 
Storage : room temperature 
Formula weight: 197.7 g 
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(10) Octanoyl-DL-camitine, C15H30NO4CI, (Sigma). 
Storage : O^C 
Formula weight: 323.9 g 
(11) Acetyl-DL-camitine hydrochloride, C9H17NO4HCI, (Sigma). 
Storage : O^C 
Formula weight: 239.7 g 
Preparation of working reagents 
(1) Buffered DTNB solution 
Concentration of each constituent: 
DTNB : 2.7 mmol/L 
HEPES : 0.5 mmol/L 
EDTA: 10 mmol/L 
Final pH: 1,5 
Preparation: 
11.915 g of HEPES and 0.292 g of EDTA was dissolved in 
distilled water, adjusted to pH 7.5 by adding 1 mol/L solution of 
NaOH. Then, 0.107 g of DTNB was added, the solution became 
slightly yellow. The final volume was adjusted to 100 ml. The 
solution was aliquoted and stored at -40® C. 
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(2) MOPS - HCl solution, 1 mmol /L 
Preparation: 
20.93 g of MOPS was dissolved in 80 ml of Imol/L HCl and 
made up to 100ml with distilled water. 
(3) KOH solution，1 mmol/L 
Preparation : 
5.611 g was dissolved in 100 ml of distilled water. 
(4) Stock Acetyl Coenzyme A solution, 12 mmol/L 
Preparation : 
1 mol/L = 809.6 g/L, 12 mmol/L = 9.7152 g/L 
25 mg of Acetyl CoA made up with 2.573 ml of distilled water 
gave approximately 12 mmol/L. 0.3 ml aliquots were stored at -
(5) Working carnitine acetyltransferase (CAT), 17.2 kU/L 
Total unit of enzyme available : 100 x 10.6 = 1060 units in 2 ml 
0.0325 ml of CAT is made up to 1ml of distilled water to give a 
final concentration of 17.2 KU/L. It was freshly prepared for 
every assay. 
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(6) Stock L-camitine solution, 1 mmol/L 
Preparation: 
0.0198 g was dissolved in 100 ml of distilled water. Aliquots were 
stored at -40^C. 
(7) Stock DL-octanoylcamitine, 1 mmol/L 
Both D-camitine and L-camitine were present after alkaline 
hydrolysis, but only the L-camitine was catalyzed by the carnitine 
acetyltransferase. As the distribution of D-camitine and L-
camitine was equal, the amount of DL-octanoylcamitine required 
was doubled. 
Preparation : 
0.0648 g was dissolved in 100 ml of distilled water. Aliquots were 
stored at -40®C. 
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(8) Working L-camitine and DL-octanoylcamitine standards 
Equal volume of stock L-camitine and stock DL-
octanoylcamitine was added to give an initial concentration of 0.5 
mmol/L and serial dilution of this combined standard gave the 
working standards. 
For free carnitine determination, only the L-camitine was 
analysed, the concentration of standards were 
125，62.6，31.3，15.6，7.8, 3.9 and 2.0 umol/L. 
For total carnitine determination, DL-octanoylcamitine was 
hydrolysed，the concentration of standands were then doubled 
250，125，62.5, 31.3, 15.6, 7.8 and 3.9 umol/L. 
(9) Working primary reagent mixtures 
0.3 ml of Acetyl-CoA was added to 1.8 ml of buffered DTNB 
solution. It should be prepared just before the analysis. 
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6.4 SPECTMEN COLLECTION 
(1) Plasma 
At least 3 ml of non-fasting whole blood preserved in 
heparin tube was required. The plasma was separated and freezed 
at -40^C or lower. Hemolysis and/or turbidity was recorded. 
(2) Urine 
5 ml of spot non-fasting urine was required. It was 
centrifuged and the supernatant was collected. The creatinine 
concentration were determined by Jaffe method (Taussky & 
Kurzmann, 1954) using Beckmen Astra 8 discrete analyser. The 
supernatant was stored at -40^C or lower. 
« 
- 4 2 -
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6.5 SAMPLE PREPARATION 
Deproteinization 
Deproteinization step was performed for plasma and urine. It was 
essential because the protein molecules would scatter light during the 
final spectrophotometric measurement and a high background 
i 
j absorbance would result. Deproteinization also helped to reduce matrix 
effect as aqueous standards were used. 
A 30,000 molecular weight cut-off ultra-spin filter was employed. 
I 400 ul of sample was pipitted into the sample reservoir of the filter 
i 1 
device. It was then centrifuged at 2，000g for one and a half hour. The 
filtrate should be clear and at least 150 ul in volume. If the filtrate was 
yellow in colour, indicating a leakage in the filter, the filtration would 
be repeated. The filtrate was collected and freezed at -40®C or lower. 
The filter used could not be reused. 
The speed of the centrifugation should not exceed 2,500g to 
prevent premature plugging of the membrane leading to very little 
filtrate output. 
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6.6 ASSAY PROTOCOL FOR FREE CARNITINE 
The following protocol was used to set up the test parameters for 
the free carnitine assay using CoBas Bio Fara (Roe et al, 1992). 
I 
GENERAL 
Measurement mode: Absorbance 
Reaction mode : Free carnitine 
Calibration mode : Standard nonlinear 
Reagent blank : Reagent / diluent 
Wavelength : 412 nm 
Decimal position : 1 
Unit : umol/L 
ANALYSIS 
P Sample : 30 ul Diluent: 15 ul 
Reagent : 30 ul 
12 Incubation : 150 seconds 
Ml : 10 seconds M2 : 140 seconds 
SRI Start R 1 : 10 ul Diluent: 5 ul 
AO Readings 
First : 1 second Number : 27 
Interval : 20 seconds 
CALCULATION 
Conversion factor : 1.0 Offs : 0.0 
Reaction direction : increasing Check : On 
Sample limit : No 
Test range Lo :No Hi: No umol/L 
Normal range Lo : No Hi: No umol/L 
Calculation steps : 1 
Calculation step A : Kinetic 
Readings first : 1 Last: 27 
Reaction Limit : No 
CALIBRATION 
Calibration interval: On request 
Standard nonlinear 
1 ： 2.0 2 : 3.9 umol/L 
3 : 7.8 4 : 15.6 umol/L 
5 : 31.3 6 : 62.5 umol/L 
7 ： 125.0 8 : No umol/L 
Deviation: No 
Calculation model : Linear regression 
Replicate : Duplicate 
Correction standard: Off 
Reagent range Lo : No Hi: No A 
Blaiik Range Lo : No Hi: No A A 
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CONTROL 
CSl Pos : No 
CS2 Pos : No 
CSS Pos : No 
REACTION MODE 
Name: Free carnitine 
1 P Parallel pipetting 
2 12 Incubation with 2 aux. 
3 SRI Start reagent 1 
4 AO Measurement cycle 
P Working primary reagent mixtures 
(DTNB, EDTA and Acetyl CoA in HEPES buffer) 
SRI Carnitine acetyltransferase 
Sample, diluent (water) and the primary reagent mixture (DTNB, 
EDTA and Acetyl CoA in HEPES) were pipetted into the cuvette and 
mixed. After incubation, the enzyme carnitine acetyltransferase was 
added. Reaction occurred and the colour product formed after an 
incubation period was monitored at 412 nm. The change of absorbance 
is read against a reagent blank and was proportional to the concentration 
of the free L-camitine. 
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6.7 ASSAY PROTOCOL FOR TOTAL CARNITINE 
The following protocol was used to set up the test parameters for 
the total carnitine assay using CoBas Bio Fara (Roe et al, 1992). 
GENERAL . 
Measurement mode: Absorbance 
Reaction mode : Total carnitine 
Calibration mode : Standard nonlinear 
Reagent blank : Reagent / diluent 
Wavelength : 412 nm 
Decimal position : 1 
Unit : umol/L 
ANALYSIS 
P Sample : 30 ul Diluent: 5 ul 
Reagent : 5 ul 
10 Incubation : 900 seconds 
SRI Start R 1 : 5 ul Diluent: 0 ul 
10 Incubation : 240 seconds 
R2 Reagent 2 :30 ul • 
12 Incubation : 150 seconds 
Ml : 10 seconds M2 : 140 seconds 
SR2 Start R 2 : 10 ul Diluent: 5 ul 
AO Readings 
First : 1 second Number: 27 
Interval : 20 seconds 
CALCULATION 
Conversion factor : 1.0 Offs : 0.0 
Reaction direction : increasing Check : On 
Sample limit : No 
Test range Lo : No Hi: No umol/L 
Normal range Lo : No Hi: No umol/L 
Calculation steps : 1 
Calculation step A : Kinetic 
Readings first : 1 Last: 27 
Reaction Limit : No 
CALIBRATION 
Calibration interval: On request 
Standard nonlinear 
1 ： 3.9 2 : 7.8 umol/L 
3 : 15.6 4 : 31.3 umol/L 
5 : 62.5 6 : 125 umol/L 
7 ： 250.0 8 : No umol/L 
Deviation: No 
Calculation model : Linear regression 
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Replicate ： Duplicate 
Correction standard: Off 
Reagent range Lo : No Hi: No A 
Blank Range Lo : No Hi: No a A 
CONTROL 
CSl Pos :No 
CS2 Pos : No 
CSS Pos : No 
REACTION MODE 
Name: Total carnitine 
1 P Parallel pipetting 
2 10 Incubation 
3 SRI Start reagent 1 
4 10 Incubation 
5 R2 Reagent 2 
6 12 incubation with 2 aux. 
7 SR2 Start reagent 2 
8 AO Measurement cycle 
P Sodium Hydroxide 
SRI MOPS-HCl 
R2 Primary working reagent mixtures 
(DTNB, EDTA and Acetyl-CoA in HEPES buffers) 
SR2 Carnitine Acetyltransferase 
Sample, diluent and sodium hydroxide were pipetted and mixed. 
During the incubation, acylcamitine was hydrolysed by sodium 
hydroxide into free carnitine and acyl group. With the addition of 
MOPS-HCl, the hydrolysis was stopped and the pH neutralized. The 
total (free and acyl) carnitine was analysed with the addition of carnitine 
acetyltransferase. 
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6.8 FACTORS AFFECTING THE PERFORMANCE OF THE 
ASSAYS 
(1) Deproteinization 
The efficiency of the assay is influenced by the choice of 
deproteinization method. Acid deproteinization and ultrafiltration 
are two common methods. They have their own advantages and 
disadvantages. 
Acid deproteinization is cheap. Both acid soluble short-
chain acylcamitine and acid insoluble long-chain acylcamitine 
can be obtained and determined. The disadvantages include lower 
sensitivity due to sample dilution, increased ionic strength. 
Moreover, a thiol oxidation step is required prior to analysis in 
order to remove the interference from other thiol compounds. 
Filtration method is expensive. Long filtration time is 
required. It can only obtain the short-chain acylcamitine from the 
filtrate because the long-chain acylcamitine is bound to the 
protein and is retained by the membrane. However, the ionic 
strength is unaltered as no salt is introduced and no dilution of the 
sample makes it become more popular in spite of its cost. Also, 
the endogenous thiol compounds will not interfere with the 
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analysis (Roe et al, 1992). 
(2) DTNB 
One of the limitation in using DTNB methods is the general 
reaction of DTNB with reducing substances present in the 
samples. As a result, the blank absorbance might be very high. 
Moreover, carnitine acetyltransferase also reacts with DTNB, 
therefore both a sample and an enzyme blank have to be 
substracted from the observed overall absorbance changes. 
Correction of both the enzyme and sample blanks can be done by 
the analyser. 
(3) HEPES and MOPS buffer 
HEPES and MOPS buffer is a competitive inhibitor for the 
enzyme carnitine acetyltransferase (Tegelaers et al, 1989). The 
catalytic centre of this enzyme has some affinity for these buffers, 
despite the fact that there is no detectable formation of acetylated 
product. To reduce these effects, higher concentration of carnitine 
acetyltransferase was employed in order to obtain acceptable 
reaction time. 
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6.9 EVALTJATTON OF FREE AND TOTAL CARNITINE 
ASSAYS 
The assay was evaluated by the following protocol: 
Precision test 
Eighteen pooled plasma filtrates were anaylsed at the same run for 
both free and total carnitine to evaluate the within-batch precision. 
For between-batch test, the pooled plasma was analysed once for 
free and total carnitine for each batch run. The pooled plasma was 
f 
divided into aliquots and freezed at -40^C or lower. One aliquot was 
used for each batch. 
Linearity check 
Total carnitine assay was performed on a serial dilution of a 




Different amounts 6f either L-camitine or Octanoyl-DL-camitine 
standards were spiked into the plasma and the spiked samples were 
analysed for free and total carnitine in triplicate. 
Sample Volume of Volume of stock dilution factor Calculated increase 
sample std (1 mmol/L) of sample (F) in carnitine conc. 
(ul) (ul) (umol/L) 
S 1000 0 - -
S + 25 960 40 24/25 25 
S + 50 920 80 49 / 50 50 
S + 100 900 100 9 / 1 0 100 
Since the sample S was diluted by the stock standard, a dilution factor (F) was 
included. 
Carnitine conc. of spiked sample - Carnitine conc. of sample S x F 
% recovery = 100% 
Expected increase in carnitine conc. 
Interference of acetvlcarnitine on free carnitine assay 
Acetylcamitine is one of the main acylcamitine in serum. In free 
carnitine assay procedure, acetylation of free carnitine also leads to the 
formation of acetylcamitine. Because of the complicated relationship, 
the interference of acetylcamitine on the determination of free carnitine 
was tested at different concentrations of acetylcamitine (7.8 to 500 
umol/L). 
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7. RESULTS OF EVALTJATTON OF TOTAL AND FREE 
CARNTTTNE ASSAYS 
7.1 CALIBRATION 
The curves were linear over the calibration range for free and 
total carnitine. For free and total carnitine, the useful calibration ranges 
were from 2 to 125 umol/L and 3.9 to 250 umol/L respectively. The 
calibration curve of free and total carnitine assay were shown in figure 
5 and figure 6 respectively. 
The absorbance of reagent blank was low and steady throughout 
the assay. The change of absorbance against time was shown in figure 
7. 
After the addition of the enzyme carnitine acetyltransferase, the 
typical change of absorbance against time was shown in figure 8. 
The use of the combined standand, octanoyl-DL-camitine and L_ 
carnitine, has the advantage that the alkaline hydrolysis step can be 
monitored as Octanoyl-DL-camitine was also hydrolysed under the same 
condition. Any deviation in this step would generate a non-linear 
calibration curve. 
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Figure 5. Calibration curve for free carnitine assay 
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Figure 6. Calibration curve for total carnitine assay 
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Figure 7. Graph of reagent blank with respect to time. 
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Figure 8. A typical reaction curve responding to time. 
-54 -
1.1 PRECTSTON 
The within- and between-batch precision at different levels are as 
follows : 
(1) Within-batch 
Free carnitine Total carnitine 
Number 18 18 
Mean (umol/L) 59.1 75.3 
S.D. (umol/L) 1.8 4.3 
C.V. ( % ) 3.0 5.7 
(2) Between-batch 
Free carnitine Total carnitine 
Number 15 15 
Mean (umol/L) 58.3 72.4 
S.D. (umol/L) 3.4 5.4 
C.V. ( % ) 5.9 7.5 
Coefficients of variation for free and total carnitine were 
acceptable for within-batch and between-batch assays. 
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7.3 TJNEARTTY RANGE 
The linearity range was at least between 2 and 250 umol/L, the 
lowest and highest calibrators respectively, and is shown in figure 9. It 
was sufficient for routine analysis for free or total plasma carnitine. 
However, for urine analysis, dilution might be required prior to analysis 
since urine carnitine levels might be over the calibration range. As 
normal subjects usually do not have very low value (less than 2 umol/L), 
the lowest detection limit was not determined. For a routine screening 
purpose, this linearity range was sufficient. 
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Linearity check 
^ m 150 ^ ^ 300 
Total carnitine concentration (umol/L) 
Figure 9. Linearity check for carnitine assay. 
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7.4 抓 COVERY 
The recovery of free and total carnitine in the assay are as follow : 
Plasma free carnitine recovery 
L-camitine standard added Mean recovery ( % ) 




Plasma total carnitine recovery 
Octanoyl-DL-camitine standard added Mean recovery ( % ) 




The results showed that the recovery of free carnitine was 
essentially 100% at the physiological range. However, the recovery for 
total carnitine was relatively low. This is due to the partial binding of the 
octanoylcamitine to plasma protein that was retained by the membrane 
during filtration. For decanoylcamitine, the recovery was only 53% (Roe 
et al, 1992). Since the majority of acylcamitines are short-chain acyl 
carnitine or acetylcamitine in normal subjects, the recovery of the 
acylcamitine up to eight carbons has been reported by other workers to 
be essentially 100% (Roe et al, 1992). 
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7.5. TNTERFERENCE OF ACETVT CARNTTTNE ON FREE 
CARNTTTNE ASSAY 
The following is the result of the interference experiment: 
Acetyl-DL-camitine added Cone, detected as carnitine 








Acetylcamitine did not interfere significantly with the free 
carnitine assay in the physiological range. At higher concentration, it 
may cause an over estimation of free carnitine. 
7.6 mSCTISSTON 
The determination of free and total carnitine concentration in 
plasma or urine by this spectrophotometric method is efficient and 
convenient. One rotor load of fourteen samples with calibration or 
twenty-eight samples without calibration can be determined for both 
fractions within one and a half hour. The reagents used are not expensive 
except for the ultra-spin filters used in the deproteinization step. The use 
of filter membrane is worthwhile because it can eliminate a lot of 
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manual steps especially for the removal of endogenous thiol compounds. 
Precision and accuracy are improved. Although minor interactions 
occur with DTNB by carnitine acetyltransferase and HEPES or even 
MOPS, these can be miminized by altering the concentration of the 
enzyme. 
The result of the evaluation can be considered as satisfactory and 
the assay can be used in the clinical study. The evaluation results are 
also very close to the results published by other study groups (Cederblad 
et al, 1986，Roe et al, 1992) based on the same methodology. 
鲁 
Acylcamitine are obtained by substracting the free from the total 
carnitine. Actually, it only measures the short-chain acylcamitine. The 
long-chain acylcamitines are retained during deproteinization. This is 
the major drawback of employing the filter. Nevertheless, these assays 
can be applied to routine laboratory for general screening of carnitine 
deficiency. 
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8. STUDY TN NORMAL SUBJECTS 
8.1 SUBJECTS 
Fifteen healthy males and fifteen healthy females with mean 
age of 28 were chosen as the control subjects. Five ml of non-fasting 
blood was taken and preserved in heparin tubes. The plasma was 
separated and stored at -40 ^C or lower prior to deproteinization. The 
samples were neither hemolysed nor turbid. 
8.2 T^ FSTTLTS OF THE NORMAT. SUBJECTS 
The results from the normal subjects are summarized in Table 1. A 
significant difference in total and acyl carnitine concentration was found 
between the two sexes (p<0.001). 
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Total carnitine Free carnitine Acylcamitine AC / FC 
TC (umol/L) FC (umol/L) AC (TC - FC) 
(umol/L) 
Female (n= 15) 
Mean 56.5 40.2 16.3 0.44 
S.D. 9.0 9.7 3.5 0.20 
Maximum 70.2 55.0 21.3 0.99 
Minimum 36.9 21.3 14.8 0.34 
Male (n= 15) 
Mean 67.6 44.4 23.2 0.53 
S.D. 6.5 6.1 3.8 0.12 
Maximum 77.8 54.0 29.7 0.77 
Minimum 56.7 32.0 15.9 0.34 
Male and Female (n = 30) 
Mean 62.1 42.3 19.7 0.49 
S D 9.5 8.2 5.0 0.17 
Maximum 77.8 55.0 29.1 0.99 
Minimum 36.9 21.3 7.9 0.18 




Our results were in general similar to those from two other studies 
(Maeda et al, 1990 & Deufel，1990). They also had a similar finding that 
total carnitine was higher in males than in females, but no sex difference 
was found in free carnitine concentration in our results. A comparison 
was shown in table 2. 
Apart from a sex difference, the carnitine level also differs in 
different age groups (Deufel, 1990) (Figure 10). The concentration is 
lowest at birth and rises gradually until aldolescent and then becomes 
steady. The range within an age group may also vary widely. This 
difference may be due to factors of fasting state, adipositas, renal 
function and, to some extent, muscular exercise. 
-63 -
Total carnitine Free carnitine 
Mean +/- S.D. Mean +/- S.D. 
(umol/L) (umol/L) 
) 
Reference Male & Female Male Female Male & Female Male Female 
this project 62.1 +/-9.5 67.6 +/- 6.5 56.5 +/- 9.0 42.3 +/- 8.2 44.4+/-6.1 40.2+/-9.7 
(n = 30) (n=15) (n=15) (n = 30) (n=15) (n 二 15) 
Maeda et al, 60.6 68.5 +/- 12.0 58.1 +/- 12.0 35.2 48.3 +/- 9.9 31.0 +/- 10.0 
1990 (n = 50) (n=12) (n = 38) (n = 50) (n=12) (n = 38) 
Deufel, 44.2-79.3 28.1 -66.4 34.8-69.5 19.3 -53.9 
1990 , (n = 23) (n = 28) (n = 23) (n = 28) 
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Figure 10. Age-dependent rise in serum carnitine concentration after 
birth. (Adapted from Deufel，1990) 
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9. PATIENTS STUDY 
9.1 PATIENTS WTTH CARDTOMYOPATHY 
9.1.1. SUBJECTS 
Fourteen patients with unknown cause of cardiomyopathy were 
investigated. 
Fourteen sex and age matched controls were also chosen from 
other patients not suffering from cardiomyopathy. 
Non-fasting plasma and spot urine from these patients were 
studied. 
9.1.2 I^ FSTTLTS OF THE STUDY 
The plasma and urine total and free carnitine concentrations from 
cardiomyopathy patients were summarised in table 3 and table 4 
respectively. 
Compared to the control group, no significant difference was 
found in plasma carnitine levels. In urine, the free carnitine 
concentration were significantly lower (p<0.005) with an elevated acyl 
to free carnitine ratio (p<0.05). Patient 1 and patient 2 had carnitine 
profiles different from the control and other patients. 
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Plasma 
Patients Sex Age Total carnitine Free carnitine Acyl carnitine AC / FC 
TC FC AC = TC - FC 
(umol/L) (umol/L) (umol/L) 
P 1 F 11yrs 40.7 18.6 22.1 1.19 
P2 F 4wks 11.1 9.6 1.5 0.16 
P3 M 8yrs 35.5 28.6 6.9 0.24 
P4 M 5yrs 62.8 43.0 19.8 . 0.46 
P5 F 4yrs 42.7 32.3 10.4 0.32 
P6 M 6yrs 36.4 26.3 10.1 0.38 
P7 F 8yrs 46.8 35.2 11.6 0.33 
P8 F 10yrs 26.7 21.1 5.6 0.27 
pg M 9yrs 37.2 33.3 3.9 0.12 
� P10 F 3yrs 26.7 24.6 2.1 0.09 
P11 M 1yrs 55.5 43.5 12.0 0.28 
P12 M 28 days 64.8 67.9 6.9 0.12 
P13 F 16yrs 33.3 29.6 3.7 0.12 
P14 M 5yrs 42.0 33.0 9.0 0.27 
Patients 
Number 14 14 14 14 
Maximum 64.8 57.9 22.1 1.19 
Minimum ” . 1 9.6 16 0.09 
Mean 40.2 31.2 9.0 0.31 
S.D. 14.4 11.9 6.1 0.28 
Controls 
Number 14 14 14 
Mean 37.9 27.8 10^ 1 0.39 
S.D. 12.2 8.6 6.2 0.22 




Patients Sex Age Total carnitine Free carnitine Acyl carnitine AC / FC 
TC FC AC = TC - FC 
umol / mmol Cr umol I mmol Cr umol / mmol Cr 
P 1 F 11yrs 54.3 11.7 42.6 3.64 
P2 F 4wks 3.0 2.0 1.0 0.50 
P3 M 8yrs 33.0 14.5 18.5 1.28 
P4 M 5yrs 14.0 3.1 10.9 3.52 
P5 F 4yrs 22.4 6.9 15.5 2.25 
P6 M 6yrs 34.9 3.0 31.9 10.63 
P7 F 8yrs 17.0 1.9 15.1 7.95 
P8 F 10yrs 33.7 9.5 24.2 2.55 
pg M 9yrs 39.8 9.1 30.7 3.37 
P10 F 3yrs 10.8 6.6 5.2 0.93 
P11 M 1yrs 11.2 1.6 9.6 6.00 
P12 M 28 days 24.5 14.4 10.1 0.70 
P13 F 16yrs 17.4 6.8 10.6 156 
P14 M 5yrs 17.4 6.8 10.6 1.56 
Patients 
Number 14 14 14 U 
Maximum 54.3 14.5 42.6 10=63 
Minimum 3.0 1.6 10 0.50 
Mean 23.8 6.9 16.9 3.32 
S.D. 13.8 4.4 11.6 2.97 
Controls “ � ， 
Number 14 14 14 14 
Mean 40.8 20 20.8 .40 
S.D. 27.4 13.2 15.2 1.20 
* Cr = Creatinine 




The plasma total carnitine level for patient 1 was not low, but the 
acyl to free carnitine ratio was very high. The urinary acyl to free 
carnitine ratio was also high. This maybe compatible with increased 
production and increased excretion causing secondary carnitine 
deficiency. 
Patient 2 had low carnitine levels both in plasma and urine. The 
deficiency of plasma carnitine would cause low urinary excretion. Since 
the acyl to free carnitine ratio was subnormal, primary carnitine 
deficiency was suspected. These two patients would be further 
investigated in another study. 
9.1.3 mSCTTSSION 
Measurement of plasma carnitine levels can be useful for 
identifying patient with primary carnitine deficiency. The pathogenesis 
of the primary carnitine deficiency is recently attributed to a genetic 
defect of carnitine transport (Tein et al，1990). Very low plasma total 




Organic acidurias, defects in beta-oxidation and some respiratory-
chain diseases are associated with cardiomyopathy. Because fatty acid 
oxidation is essential for energy production in the heart muscle and 
carnitine is crucial for the transport of long-chain fatty acid into the 
inner mitochondrial membrane, deficient in carnitine would affect the 
muscle function and cause cardiomyopathy. Evaluation of plasma 
carnitine levels are helpful in the identification of patients being 
suspected of secondary carnitine deficiency. The laboratory hallmarks 
are increased ratio of acyl to free carnitine and a reduced free carnitine 
level in plasma. This should be confirmed by identifying the organic 
acids involved by chromatographic technique and enzymatic studies of 
the defective enzyme. 
« 
Out of the fourteen patients in this study, patient 2 was suspected 
of having primary carnitine deficiency while patient 1 was suspected of 
having secondary carnitine deficiency. All of them were classified as 
having "idopathic" cardiomyopathy clinically. Consequently 
measurement of carnitine is very useful in patients with cardiomyopathy. 
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9.2 PATIENTS WTTH MFTABOLTC DISEASES 
9.2.1 SUBJECTS 
The original plan for this group of patients was to study the 
carnitine status for all organic acidurias diagnosed during the year of the 
project. However, no definitive organic acidurias was diagnosed in the 
Hospital this year. Only fourteen cases of non-specific organic acidurias 
were detected. The organic acid excretion included 4-OH-n-butyric acid, 
4- OH-phenyllactic acid and lactic acid etc. The urine samples of these 
fourteen specimens were retrieved for measurement of urine carnitine. 
Fourteen urine samples with negative metabolic screening and organic 
acid results from sex and age matched control were also studied. 
9.2.2. TTFSM TS OF THE STUDY 
The carnitine levels of the fourteen patients were summarised in 
table 5. To correct for the difference in daily urine output, the total and 
free carnitine were expressed as umol per mmol creatinine. Patient 9 had 
a very high total and free carnitine excretion. Therefore, this value had 
been deleted from the statistical calculation for both the patients and the 
controls. The carnitine levels were age dependent with large within age 
group variation as shown in figure 10. This might explain the large 
standard deviation observed for the patients and the controls. 
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Sample Sex/Age Total carnitine Free carnitine Acyl carnitine A C / F C 
^ TC FC AC = TC - FC 
umol I mmol Cr umol / mmol Cr umol / mmol Cr 
P1 F/4days 15.7 13.5 2.2 0.16 
P2 F/7yrs 21.0 3.0 18.0 6.00 
P3 F M d a y s 178.1 121.1 57.0 0.47 
P4 F/5wks 60.8 52.9 7.9 0.15 
P5 M/28 mths 18.7 10.2 8.5 0.82 
P6 F/3wks 45.3 33.5 11.8 0.35 
P7 F/4wks 46.0 14.7 31.3 2.12 
P8 F/13 days 109.3 75.8 33.5 0.44 
pg F/4wks 4513.6 2063.6 2460.0 1.20 
P10 M/3days 45.0 18.1 26.9 1.49 
P11 M/5mths 48.0 19.1 28.9 1.51 
P12 M M mths 13.1 7.4 5.7 0.77 
P13 M/1mths 18.7 15.8 2.9 0.18 
P14 M/7days 13.3 6.6 6.7 1.02 
Patients (exclude P9) 
Number 13 13 13 13 
Mean 48.7 30.1 8.6 
S.D. 46.1 33.3 15.7 1.57 
Controls (exclude the control for P9) 
Number 13 13 13 
Mean 49.1 25.1 24.0 0.9 
S.D. 37.5 13.7 30.2 0.9 
* Cr = Creatinine 
Table 5 Urine total and free carnitine concentration in patients with 
metabolic disorders. 
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There was no significant difference between the means of the 
patient and control groups. None of the patient, apart from patient 9，had 
elevated urinary acylcamitine excretion above the control. 
Consequently, it was interpreted that, apart from patient 9，none of the 
subjects had significant camitinuria. Patient 9 had total, free and acyl-
camitine level markedly above the control value (> 2.S.D.). The acyl to 
free carnitine ratio was not significantly different from control. The high 
level of the carnitine excretion in patient 9 may reflect some underlying 
metabolic abnormality which was related with the carnitine metabolism 
and would be further investigated in another study. 
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DTSCTJSSTON 
Many factors would affect the urinary excretion of free and acyl 
carnitines. Organic aciduria is one of the causes leading to increased 
excretion of acylcamitine with a high ratio of acyl to free carnitine. 
Although the output of acylcamitines from patient 9 was very high, the 
ratio of acyl to free carnitine was not different from normal. The cause 
for such findings would be investigated in another study. 
Carnitine is a small molecule and it is freely filtered through the 
glomerli and actively reabsorbed in the renal tubules. Any defects in the 
tubular transport would hinder reabsorption, and urinary excretion of 
carnitine would be increased. Steinmann et al (1987) reported that 
patients with Fanconi syndrome had decreased tubular reabsorption and 
increased urinary loss of carnitine. Whether Fanconi syndrome would 
lead to carnitine deficiency is not clear. 
In general, it may not be possible to determine the underlying 
defect in carnitine metabolism based on the urinary carnitine levels. 
Plasma sample should be investigated as well. 
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9.3 PATTENTS ON VALPROIC ACID THERAPY 
9.3.1 SUBJECTS 
Plasma samples from the patients taking valproic acid were 
studies for the total and free carnitine levels. The patients were on 
valproic acid alone or together with other anticonvulsant drugs. The 
results were compared with those of the thirty healthy controls. 
9.3.2. T^ FSTTT TS OF THE STUDY 
The total and free carnitine concentrations were summarised in 
table 6. Total and free carnitine were significantly decreased comparing 
to the controls (p<0.001). The acylcamitine and the ratio of acyl to free 
carnitine were increased with (p< 0.001). Among these twenty-five 
patients, twelve of them had a total carnitine less than 2 S.D. from the 
control mean. This results were in line with other similar studies (Riva 
et al, 1993; Rodriguez-Segade et al, 1989). 
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- Total carnitine Free carnitine Acylcamitine AC/FC 
TC FC AC = TC -FC 
(umol/L) (umol/L) (umol/L) 
Patients ( n= 25) 
Mean 43.6 28.1 15.6 0.67 
S.D. 18.2 13.5 11.0 0.60 
Maximum 77.8 56.7 40.0 2.70 
Minimum 7.9 4.3 3.0 0.09 
Controls ( n = 30) 
Mean 60.0 49.8 10.2 0.22 
S.D. 9.2 9.3 4.3 0.11 
Table 6. Plasma total and free carnitine concentrations in patients 




Although valproic acid therapy would definitely cause 
carnitine deficiency, the extent of its effect is still unclear. In this study, 
the results demonstrated that valproic acid did cause a general decrease 
in carnitine levels. Other factors such as the duration of therapy, drug 
dosage, polytherapy with other anticonvulants drugs and age of patient 
were not considered. As valproic acid is thought to inhibit beta-
oxidation, the accumulated organic acids require free carnitine to carry 
them away from the mitochondria. In addition, valproic acid is 
metabolised to form valproyl CoA, and is bound to the carnitine as 
valproylcamitine being transported out of the mitochondria (Coulter & 
Zaidman, 1988). As a result, acylcamitine is increased in the plasma and 
finally be excreted in the urine with the consequence of excess loss of 
carnitine associated with the acyl groups. Hence, both total and free 
carnitines are decreased and the ratio of acyl to free carnitine increased. 
Besides valproic acid therapy, other organic acidurias leading to excess 
accumulation ofunmetabolised organic acids would give similar picture. 
In a recent study, a significant drop of carnitine level was detected two 
weeks after the start of valproic acid therapy and it continued to decrease 
(Riva et al, 1993), showing a relation to the duration of therapy. The 
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effect of carnitine supplementation is supported by the study from 
Sakemi et al (1992). They showed that the half-life of valproic acid was 
prolonged in adult patients without carnitine supplementation. After 
treatment with carnitine, the half-life of valproic acid was returned 
towards normal. A similar study also supported that carnitine 
supplementation was beneficial (Melegh et al, 1990). In addition, it 
showed that a considerable part of oral carnitine was involved in the 
elimination of acyl groups from the body. Hence, carnitine replacement 
seemed to normalize the carnitine levels in the body. In this study, 
twelve patients had total carnitine concentration less than 2 S.D. from 
the control mean, carnitine supplementation is most likely required. 
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9.4 PATIENTS ON RENAT. DTAT.YSTS AND AFTER 
TRANSPTANTATTON 
9.4.1 SUBJECTS 
Three groups of renal patients were studied : 
(1) Eighteen patients receiving hemodialysis; 
(2) Fifteen patients on continous ambulatory peritoneal 
dialysis (CAPD) 
(3) Sixteen patients after renal transplantation 
The results were compared with those from the thirty normal 
healthy controls. 
9.4 .2 .應TTT TS OF THE STUDY 
The total and free carnitine concentrations from different patient groups 
are summarized in table 7. There was no significant difference in total 
carnitine among all patients and controls. Haemodialysis and CAPD 
patients had low free carnitine and high acyl carnitine concentrations. 
The ratios of acyl to free carnitine were also high. The results from renal 
transplanted patients tended to lie between the patients on dialysis and 
control. 
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Total carnitine Free carnitine Acylcamitine AC/FC 
TC FC AC = TC -FC 
(umol/L) (umol/L) (umol/L) 
Controls (n = 30) 
t 
Mean 60.0 49.8 10.2 0.22 
S.D. ‘ 9,2 9.3 4.3 0.11 
Renal transplantation (n = 16) 
Mean 58.0 39.6 18.4* 0.53* 
S.D. 16.8 16.0 8.1 0.30 
Haemodialysis (n= 18) 
Mean 67.1 30.7* 36.4* # 1.39* # 
S.D. 16.8 11.3 9.3 0.73 
CAPD (n= 15) 
Mean 58.5 25.3* 33.3* 1.34* 
S.D. 35.7 11.8 29.3 1.22 
* significant difference with the controls (P<0.001) 
# significant difference with the renal transplanted patients (P< 0.001) 
Table 7. Plasma total and free carnitine concentration in renal 




Both hemodialysis and CAPD patients had a high acyl to free 
carnitine ratio compared with the normal controls. Since the 
acylcamitines are larger molecules, it may not be dialysed efficiently, 
the smaller free carnitines are able to diffuse across the dialysis 
membrane. This may account for the decreased free carnitine level and 
increased acylcamitine levels. In addition, renal dialysis patients have 
limited intake of red meat and dairy products which are rich sources of 
carnitine. Therfore，the reduced absorption of carnitine in the diet may 
further decrease the available free carnitine in the body. In renal 
transplanted patients, the carnitine profile was greatly improved as 
compared with the dialysis patients. This indicates that renal 
transplantation is effective in returning carnitine to normal. 
Some clinical conditions which are not infrequently seen in 
dialysis patients have been suggested to be related to carnitine 
metabolism. These include impairment of muscle function and 
metabolism, muscle weakness and myopathy, cardiomyopathy, lipid 
abnormalities, cardiac dysfunction and arrhythmias. Intradialytic 
symptoms such as muscle cramps, cardiac arrhythmias and hypotension 
are often encountered and may be related to carnitine metabolism. L-
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carnitine supplementation was found to be useful in these patients 
(Taggart et al, 1986). It can restore the ratio of acyl to free carnitine 
compensating for the failure of kidney tubular function. Although not all 
of the published studies favoured carnitine supplementation (Table 8)， 
a great majority showed improvement. 
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Published studies (n = 42) reporting effect of L-camitine supplementation on various 
parameters in haemodlalysis patients (n 二 600) 
Parameters Improvement No improvement 
Lipids 21 9 
Dialytic morbidity 5 ‘ 
Skeletal function 5 0 
Cardiac function 5 ‘ 
Haematocrit 6 ‘ 
Others ^ 一 
Table 8. Effect of L-camitine supplementation in hemodialysis 
patients. 
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10. CENERAL DTSCTJSSTON 
Carnitine is an essential compound in humans (Paulson & Shug， 
1981). It was discovered approximately 80 years ago and chemically 
characterized as a small, highly polar, water soluble compound having 
a molecular weight of 162. In 1959, Fritz demonstrated that carnitine 
played an important role in mitochondrial beta-oxidation of long-chain 
fatty acids (Fritz, 1959). Since then, several major roles of carnitine have 
been found, including the buffering of mitochondrial acyl CoA / CoA 
couple, acting as a scavenger for acyl groups, and carrying branched-
chain amino acid metabolism. A number of reports on cellular 
intermediary metabolism has shown that in the presence of carnitine, a 
large amount of specific acylcamitine are generated within the 
mitochondria. The production and efflux of acylcamitines from 
mitochondria is tissue and substrate-specific and dependent on carnitine 
concentration (Lysiak et al, 1986). 
The acetylated form of carnitine, acetylcamitine, is the major 
acylcamitine found in tissues (Bieber et al, 1982). Hence free carnitine 
and to a much lesser extent, acetylcamitine can be considered as the 
shuttling forms of carnitine found in both intracellular and extracellular 
fluids respectively. 
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Carnitine can be synthesized in the body, even though an 
exogenous supply of carnitine is necessary to balance the daily 
requirements (Angelini et al, 1979). The principal sources are red meat 
and dairy products. Over 90% of carnitine is present in skeletal and 
cardiac muscles, and the remainder is found in liver, kidney and other 
tissues. Extracellular fluids, including plasma, contain approximately 
0.6% of the body's total carnitine (Rizza et al, 1992). Tissue carnitine 
concentration exceed the plasma concentraion by one or two orders of 
magnitude indicating the need for an energy-dependent active transport 
mechanism to maintain this membrane gradient ( Tein et al, 1990). 
Different transport systems had been identified and characterized 
in all tissues in which carnitine plays a physiological role. Most data 
suggests that these systems are sod ium-dependent active transport 
mechanisms, but definite observations are not available (Brass, 1992). 
The properties of these systems determine many of the characteristics of 
in vivo carnitine homeostasis and the fate of exogenous carnitine. 
Among these, the mitochondrial translocase is well characterized 
(Pande, 1975), which is responsible for the transport of acylcamitine 
from the inner mitochondrial space into the mitochondria and transport 
the free carnitine out. An important aspect this mitochondrial carnitine 
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transport is its potential regulation in intact cells. Mitochondrial 
translocase activity can be increased by increasing the 
intramitochondrial carnitine content (Parvin & Pande, 1979). In addition, 
the cellular distribution of carnitine can be altered. With ischaemia，the 
percentage of total myocardial carnitine present in the mitochondria 
increases from 8% to 25% (Idell-Wenger et al, 1978). Understanding of 
the transport system is also critical for therapeutic considerations such 
as how to deliver carnitine to a specific tissue and the best way to 
enhance tissue acylcamitine elimination in conditions like organic 
acidurias. 
The most sensitive method for carnitine determination in routine 
laboratory was the "radioenzymatic" assay first developed by Cederblad 
& Lindstedt (1972). However, due to the potential danger and the higher 
cost associated with the handling of radioisotopes, less sensitive 
spectrophotometric method employing the enzyme carnitine 
acetyltransferase is preferred. The assay is automated by CoBas Bio Fara 
in order to improve reproducibility and speed of analysis. Both precision 
and recovery are satisfactory. 
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In order to investigate the metabolic disorders associated with the 
production and the excretion of carnitine esters, the simple assay of free 
and total carnitine is no longer satisfactory. The need for a sensitive, 
specific and possibly direct assay of carnitine esters must be used. 
Chromatographic method allows the separation and eventually the 
quantitation of various carnitine esters for a given sample at a single 
run. However, when the problem is related to the exact identification of 
the chemical structure of acylcamitines, mass spectrophotometry must 
be employed. Indeed, this technique allows the initial characterization 
of disease-specific acylcamitines (Millington et al, 1984). 
Since fatty acid oxidation is essential for ketone body synthesis 
in the liver and for energy production in the muscle, and carnitine is 
crucial for long-chain fatty acid oxidation, disorders associated with 
carnitine deficiency would be expected to impair liver and muscle 
functions. Carnitine deficiency is recognized as a cause of human 
myopathy by Engel and Angelini (1973). Since then, and as the methods 
to measure the carnitine concentration become more available, it is clear 
that carnitine deficiency is a relatively common finding in patients with 
a number of inherited metabolic and acquired diseases : both primary 
carnitine deficiencies (Treem et al, 1988) and secondary carnitine 
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deficiencies are identified (Stanley, 1987). The association of human 
diseases with critically low tissue carnitine suggested a therapeutic role 
for carnitine. 
Two forms of primary carnitine deficiency have been described, 
myopathic and systemic. However, the definition of "primary" carnitine 
deficiency for most cases reported in the literature is based on negative 
criteria (i.e. lack of evidence for an associated genetic or acquired 
disorder capable to lower tissue carnitine stores) and many of the earlier 
cases have undergone reassessment during the past decade in light of 
new information (Tein et al, 1990). Indeed, the pathogenesis of these 
earlier cases of carnitine deficiency is obscure, although different 
possible mechanisms have been suggestive. Lack of receptors for 
carnitine in skeletal muscle in muscle carnitine deficiency and defective 
carnitine biosynthesis or generalized absence of carnitine receptors in 
systemic carnitine deficiency have been proposed, but never proven 
(Engel，1986). Primary carnitine deficiency is now recognized as a true 
nosological entity characterized by progressive cardiomyopathy, low 
carnitine in plasma, heart, muscle and liver. Lipid accumulation in 
skeletal muscle and other organs, and a defect in carnitine transport 
which canbedmonstratedinculturcdfihtoblastsCreinetat 1990). 
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Secondary carnitine deficiencies include numerous genetic and acquired 
conditions which are associated to a depletion of tissue carnitine stores. 
Among the genetic causes of secondary deficiency, the most frequently 
reported are the organic acidurias, such as propionic, methylmalonic and 
isovaleric acidurias (Chamlers et al, 1984)，and genetic defects of beta-
oxidation, such as short-chain acyl CoA dehydrogenase (SCAD), 
medium-chain acyl CoA dehydrogenase (MCAD) and long-chain acyl 
CoA dehydrogenase (LCAD) deficiencies (Stanley, 1987). 
Fourteen paediatric patients with "idiopathic" cardiomyopathy 
were investigated for total and free carnitine levels. One of the patients, 
who was a one month old girl, had plasma total carnitine concentration 
of 11.1 unol/L and free carnitine concentration of 9.6 umol/L. Her spot 
urine gave 3.0 umol/mmol Cr and 2.0 umol/mmol Cr of total and free 
carnitine levels respectively. The overall decrease in total and free 
carnitine levels in plasma and urine when compared with control group 
suggested that this patient might suffer from primary systemic carnitine 
deficiency. Among the patients with systemic carnitine deficiency, a 
subgroup is characterized by the peculiar phenotype of progressive 
dilatative cardiomyopathy which, untreated, leads to death. Carnitine 
content is low in the patients' muscle, heart, liver and plasma. The 
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disease is described in familial form, suggesting autosomal recessive 
inheritance (Tripp et al, 1981). Although the reported patients have a 
generalized deficiency of carnitine in tissues, signs of liver and muscle 
dysfimction are generally limited to hypoglycaemia and hypotonia, and 
the pathology is confined to progressive, dilatative, life-threatening 
cardiomyopathy. Therefore, this patient may belong to this subgroup, 
but further investigation should be done before any conclusive diagnosis 
is made. Clinical response to carnitine supplementation would be 
dramatic. Treated patients soon recover a normal heart function and can 
perform life, whilst untreated patients die of cardiac insufficiency at an 
early age (Tripp et al, 1981). Excellent therapeutic results with carnitine 
supplementation have been reported (Tein et al, 1990) with this disorder. 
Although some degree of clinical heterogeneity was suggested by the 
description of infants (Treem et al, 1988) with hypoketonic 
hypoglycaemia and marked hypotonia, but absence of cardiac 
involvement, a recent overview shows that most patients have either 
cardiomyopathy or hypoglycaemia, or both (Tein et al, 1990). 
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Another female patient, eleven years old, had plasma total and 
free carnitine levels of 40.7 umol/1 and 18.6 umol/L respectively. Her 
urine total and free carnitine levels were 54.3 umol/mmol Cr and 11.7 
umol/mmol Cr respectively. The plasma and spot urine acylcamitine 
were 22.1 umol/L and 42.6 umol/mmol Cr respectively. The calculated 
acyl to free carnitine ratio in plasma and urine were 1.19 and 3.64 
respectively. Compared with the sex and age matched control groups, 
the acylcamitine and acyl to free carnitine ratio were elevated and the 
free carnitine was decreased. This results suggested secondary carnitine 
deficiency. Several inborn errors of metabolism may cause 
cardiomyopathy (Kohlschutter & Hausdorf，1986). These inherited 
defects may roughly be divided into two main groups : the "small" 
molecule diseases mainly include organic acidurias, beta-oxidation 
defects and disorders of the respiratory chain; and the "large" molecule 
diseases include glycogen and lysosomal storage disease (Applegarth et 
al，1989). In "large" molecule diseases, the clinical phenotype and the 
multiorgan involvment are helpful in the diagnosis, while in "small" 
molecule disease, specific biochemical investigations are needed to 
define the underlying enzymatic defects. This patient might be due to 
"small" molecule disease although further investigation was required. 
-91 -
The rest of the patients did not give any distinctive results from 
the control groups. These patients might suffer diseases which had no 
relationship to the carnitine profile or they might have "large" molecule 
diseases. 
Fourteen spot urine samples which were found to have positive 
metabolic screening were analysed for the total and free carnitine levels. 
These patients were suspected of having some inborn errors although 
no distinctive diagnosis was made. One of the patient had 4514, 2054 
and 2460 umol/mmol Cr for total, free and acycamitine levels 
respectively. Such high carnitine excretion might be due to the tubular 
defects, so reabsorption of carnitine was impaired. However, in patients 
with Fanconi's syndrome, more generalized defects of proximal tubule, 
decreased tubular reabsorption and increased urinary loss of carnitine 
have been reported (Steinmann et al, 1987). They also observed good 
correlation between valine and carnitine tubular reaborption, however, 
they concluded that these two substances did not share the same 
absorptive mechanisms. At this point, it is unclear whether children with 
Fanconi's syndrome suffer from carnitine deficiency. Defects in tissue 
uptake might also lead to excretion of excess carnitine. However, no 
possible diagnosis was made and further investigation was required. 
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Some patients treated with valproic acid excrete valproylcamitine 
and have low concentration of free carnitine with an increased acyl to 
free ratio (Riva, 1993). Valproic acid is a branched-chain acid (2-propyl-
pentenoic acid) which gives rise to valproyl CoA in mitochondria. In 
order to remove these unmetabolised compounds, carnitine has to bind 
to it and transport these carnitine esters out of the mitochondria and 
excrete through the urine. Implicitly, the toxicity of vaplroic acid results 
in carnitine loss. Patients with valproic acid therapy under investigation 
had shown that both total and free carnitine were decreased and the acyl 
to free carnitine was raised. 
Patients with renal replacement, either under hemodialysis or 
continuous ambulatory peritoneal dialysis (CAPD) indicated that free 
carnitine was decreased but acylcamitine was raised, as a result, the acyl 
to free ratio was high. No significant difference from carnitine profile 
was found between the groups These results agreed with the data shown 
I 
by other study groups (Ahmad, 1992). With progressive renal disease, 
the tubular handling of carnitine and acylcamitine becomes abnormal. 
The preferential reabsorption of free carnitine and excretion of 
acylcamitine by the renal tubule is impaired. This leads to marked 
increase in blood concentration of acylcamitine (Rodriguez-Segade et 
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al, 1985). In patients who are not on dialysis, both free and total 
carnitine levels are increased and the ratio of acyl to free carnitine is 
high. 
In this study, the free carnitine and the acyl to free carnitine ratio 
of renal replacement patients were still high. The diet of the patients 
also influence the carnitine levels as meat and dairy products are a rich 
source of carnitine. Patients on dialysis have limited intake of these food 
items. This may cause a decrease of free carnitine level. Since carnitine 
is a small and water-soluble molecule, it is freely dialysed，resulting in 
as much as a 75% decline in plasma concentration during one 
hemodialysis session (Rumpf et al, 1983). As kidney is one of the major 
sites of carnitine synthesis, it is thought that endogenous synthesis might 
be impaired with the loss of renal parenchyma. It was proposed that 
patients on renal dialysis are camitine-deficient. This contention has 
been disputed for several reasons (Nilsson-Ehle & Cederblad，1985 & 
Fagher et al, 1985). The total normal urinary loss are compatible to, or 
exceed, the dialytic loss of carnitine; studies have shown that plasma 
concentration of total carnitine is either well within normal range or 
even slightly elevated (Golper et al, 1990). It has also been argued that 
although the carnitine level during the dialysis declines quite 
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significantly, a few hours after dialysis, it is returned to predialysis level. 
This repletion presumably occurs from the tissue stores (Ahmad, 1992). 
Patients with renal transplantaion had significant improvement in 
carnitine profile, which approached to normal. The improvement was 
probably due to the normal functioning of the transplanted kidney. 
Carnitine supplementation in renal replacement patients had been 
suggested. Most study had a positive response on various functional 
parameters such as lipid level, dialytic morbidity, skeletal function, and 
cardiac function, etc (Ahmad, 1992). 
In conclusion, four different patient groups were investigated for 
abnormality in carnitine metabolism. In the first two groups of patients 
with suspected inborn errors of metabolism and "idiopathic" 
cardiomyopathy, their underlying defects may or may not be related to 
carnitine metabolism. So, for these patients, screening for abnormal 
carnitine levels serve to eliminate the rare metabolic inborn defects such 
as the m e d i u m -chain acyl CoA dehydrogenase deficiency which may not 
be clinically apparent or detected by routine biochemical tests. 
The other two groups of patients with valproic acid therapy and 
renal diseases, they obviously have secondary carnitine deficiency. 
Instead of screening for any abnormality, carnitine levels are monitored 
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because carnitine supplementation has beneficial effects. 
Therefore, two purposes can be achieved by carnitine 
determination. It can be a routine screening test for carnitine related 
disorders, those giving abnormal and unexplained results should then be 
further investigated by special techniques. For those with explained 
carnitine deficiency, carnitine measurement can monitor the degree of 
deficiency or the response of the body to carnitine supplementation. 
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